Long-term drug treatment of GERD: Economic issues for formulary decision makers

Disease Management and Health Outcomes

Volumn 12, Issue 6, 2004, Pages 399-407

  Chan, James ^a,c   Levin, Theodore R ^b  

^a KAISER PERMANENTE   (United States)

^b KAISER PERMANENTE MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIMETIDINE; ESOMEPRAZOLE; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; NIZATIDINE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE;

COST CONTROL; DRUG COST; DRUG EFFICACY; DRUG INDICATION; GASTROESOPHAGEAL REFLUX; HUMAN; LONG TERM CARE; MEDICAL DECISION MAKING; OUTCOMES RESEARCH; PRACTICE GUIDELINE; QUALITY ADJUSTED LIFE YEAR; REVIEW; SYSTEMATIC REVIEW;

EID: 11144317315     PISSN: 11738790     EISSN: None     Source Type: Journal    
DOI: 10.2165/00115677-200412060-00007     Document Type: Review

References (34)

1. Locke GR, Talley NJ, Fett SL. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 1997; 112 (5): 1448-56
2. Bieszk N, Kale-Pradhan PB. The efficacy of extended-interval dosing of omeprazole in keeping gastroesophageal reflux disease patients symptom free. Ann Pharmacother 1999; 33 (5): 638-41
3. Galmiche JP, Bruley des Varannes S. Symptoms and disease severity in gastroesophageal reflux disease. Scand J Gastroenterol Suppl 1994; 201: 62-8
4. Sonnenberg A. Cost effectiveness of competing strategies to prevent or treat GORD-related dysphagia. Pharmacoeconomics 2000; 17 (4): 391-401
5. Falk GW. Reflux disease and Barren's esophagus. Endoscopy 1999; 31 (1): 9-16
6. DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. The Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol 1999; 94 (6): 1434-42
7. Hallerback B, Unge P, Carling L, et al. Omeprazole or ranitidine in long-term treatment of reflux esophagitis: the Scandinavian Clinics for United Research Group. Gastroenterology 1994; 107 (5): 1305-11
8. Wesdorp IC, Dekker W, Festen HP. Factors predicting relapse during maintenance treatment with famotidine in patients with healed reflux esophagitis: Dutch Esophagitis Study Group. Clin Ther 1997; 19 (5): 1048-57
9. Vigneri S, Termini R, Leandro G, et al. A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med 1995; 333 (17): 1106-10
10. Spechler S, Lee E, Ahnen D. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial. JAMA 2001; 285: 2331-8
11. Levin TR, Schmittdiel JA, Kunz K, et al. Costs of acid-related disorders to a health maintenance organization. Am J Med 1997; 103 (6): 520-8
12. Holzer SS, Juday TR, Joelsson B, et al. Determining the cost of gastroesophageal reflux disease: a decision analytic model. Am J Manag Care 1998; 4 (10): 1450-60
13. DeVault KR. Managed care issues in the treatment of gastroesophageal reflux disease. Am J Manag Care 2000; 6 (16 Suppl.): S871-5
14. Lipsey RJ. Institutional formularies: the relevance of pharmacoeconomics analysis to formulary decisions. Pharmacoeconomics 1992; 1 (4): 265-81
15. Jacobs P, Bachynsky J, Baladi J. A comparative review of pharmacoeconomic guidelines. Pharmacoeconomics 1996: 8 (3): 182-9
16. Hillman AL, Schwartz JS, Pauly MV et al. Task force on principles for economic analysis of health care technology: economic analysis of health care technology. Ann Intern Med 1995; 122: 61-70
17. Drummond MF, O'Brien B, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. New York: Oxford University Press, 1998
18. Mason J. The generalizability of pharmacoeconomic studies. Pharmacoecomics 1997; 11 (6): 503-14
19. Karnon J. Brown J. Selecting a decision model for economic evaluation: a case study and review. Health Care Manag Sci 1998; 1 (2): 133-40
20. Dean BB, Siddique RM, Yamashita BD, et al. Cost-effectiveness of proton-pump inhibitors for maintenance therapy of erosive reflux esophagitis. Am J Health Syst Pharm 2001; 58 (14): 1338-48
21. Ofman JJ, Yamashita BD, Siddique RM, et al. Cost effectiveness of rabeprazole versus generic ranitidine for symptom resolution in patients with erosive esophagitis. Am J Manag Care 2000; 6 (8): 905-16
22. Sonnenberg A, Inadomi JM. Becker LA. Economic analysis of step-wise treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1999; 13 (8): 1003-13
23. Goeree R, O'Brien B, Hunt R, et al. Economic evaluation of long-term management strategies for erosive oesophagitis. Pharmacoeconomics 1999; 16 (6): 679-97
24. Goeree R, O'Brien B, Blackhouse G, et al. Cost-effectiveness and cost-utility of long-term management strategies for heartburn. Value Health 2002; 5 (4): 312-28
25. Gerson LB, Robbins AS, Garber A, et al. A cost-effective analysis of prescribing strategies in the management of gastroesophageal reflux disease. Gastroenterology 2000; 95: 395-407
26. Stalhammar NO, Carlsson J, Peacock R. et al. Cost effectiveness of omeprazole and ranitidine in intermittent treatment of symptomatic gastro-oesophageal reflux disease. Pharmacoeconomics 1999; 16 (5 Pt 1): 483-97
27. Harris RA, Kuppermann M, Richter JE. Proton pump inhibitors or histamine-2 receptor antagonists for the prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis. Am J Gastroenterol 1997; 92 (12): 2179-87
28. Birbara C, Breiter J, Perdomo C, et al. Rabeprazole for the prevention of recurrent erosive or ulcerative gastro-oesophageal reflux disease, Rabeprazole Study Group. Eur J Gastroenterol Hepatol 2000; 12 (8): 889-97
29. Thjodleifsson B, Beker JA, Dekkers C, et al. Rabeprazole versus omeprazole in preventing relapse of erosive or ulcerative gastroesophageal reflux disease: a double-blind, multicenter, European trial. The European Rabeprazole Study Group. Dig Dis Sci 2000; 45 (5): 845-53
30. Haque M, Wyeth JW, Stace NH, et al. Prevalence, severity and associated features of gastro-oesophageal reflux and dyspepsia: a population-based study. N Z Med J 2000; 113 (1110): 178-81
31. Weinstein MC, Toy EL, Sandberg EA, et al. Modeling for health care and other policy decisions: uses, roles, and validity. Value Health 2001; 4 (5): 348-61
32. Hill S, Andrew M, Henry D. Problems with the interpretation of pharmacoeconomic analyses: a review of submissions to the Australian Pharmaceutical Benefits Scheme. JAMA 2000; 283 (16): 2116-21
33. Inadomi JM. On-demand and intermittent therapy for gastro-oesophageal reflux disease: economic considerations. Pharmacoecomics 2002; 20 (9): 565-76
34. O'Connor JB, Provenzale D, Brazer S. Economic considerations in the treatment of gastroesophageal reflux disease: a review. Am J Gastroenterol 2000; 95 (12): 3356-64